These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6228613)

  • 21. Local immune response in experimental pyelonephritis in the rabbit. II. Lymphocyte stimulation by lipopolysaccharide of infecting organism.
    Smith JW
    Immunology; 1975 Dec; 29(6):1077-85. PubMed ID: 1104473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular immunity in pyelonephritis: inhibition of the spleen cell response to the mitogen concanavalin A.
    Williams TW; Friedlander AM; Lyons JM; Braude AI
    Cell Immunol; 1974 Oct; 14(1):33-8. PubMed ID: 4619354
    [No Abstract]   [Full Text] [Related]  

  • 23. Quantitation of immunoglobulin-bearing lymphocytes and the lymphocyte response to PHA in experimental pyelonephritis.
    Miller TE; Simpson G; Ormrod DJ
    Clin Exp Immunol; 1975 Sep; 21(3):474-84. PubMed ID: 1081935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide.
    Diamantstein T; Willinger E; Reiman J
    J Exp Med; 1979 Dec; 150(6):1571-6. PubMed ID: 159940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of immunization with Escherichia coli J5 on the course of experimental pyelonephritis in rats].
    Straube E; Naumann G; Broschewitz U
    Z Urol Nephrol; 1988 Apr; 81(4):247-55. PubMed ID: 3041706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Mar; 44(3):1275-80. PubMed ID: 6229330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary results of the vaccine treatment of chronic pyelonephritis in animal experiments].
    Straube E; Broschewitz U; Schill H; Naumann G
    Z Urol Nephrol; 1984 Jul; 77(7):401-5. PubMed ID: 6385543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Local immunity -- a protection against experimental pyelonephritis].
    Kaijser B
    Lakartidningen; 1979 Oct; 76(40):3403-4. PubMed ID: 388121
    [No Abstract]   [Full Text] [Related]  

  • 29. Lymphocyte-macrophage co-operation during induction of T-suppressor cell activity in rats with adjuvant arthritis.
    Binderup L
    Ann Rheum Dis; 1983 Dec; 42(6):687-92. PubMed ID: 6228199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen-specific T contrasuppressor factor in cell-mediated immunity: interactions leading to eradication of the tolerant state.
    Ptak W; Bereta M; Ptak M; Gershon RK; Green DR
    J Immunol; 1984 Sep; 133(3):1124-30. PubMed ID: 6205065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Human bone marrow suppressor cells].
    Petrov RV; Khaitov RM; Sidorovich IG; Gubarev MI; Savinov VA
    Dokl Akad Nauk SSSR; 1984; 274(1):207-10. PubMed ID: 6231171
    [No Abstract]   [Full Text] [Related]  

  • 32. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
    Awwad M; North RJ
    Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against experimental pyelonephritis by antibodies to pili.
    Silverblatt FJ; Weinstein R; Rene P
    Scand J Infect Dis Suppl; 1982; 33():79-82. PubMed ID: 6127805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.
    Buccione C; Fragale A; Polverino F; Ziccheddu G; Aricò E; Belardelli F; Proietti E; Battistini A; Moschella F
    Int J Cancer; 2018 Mar; 142(5):976-987. PubMed ID: 28975621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats.
    Brooks SJ; Lyons JM; Braude AI
    Am J Pathol; 1974 Feb; 74(2):345-58. PubMed ID: 4590645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of suppressor cell activities by cyclophosphamide in breast cancer patients.
    Kuroi K; Sato Y; Yamaguchi Y; Toge T
    J Clin Lab Anal; 1994; 8(3):123-7. PubMed ID: 8046538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes.
    Nazimek K; Ptak W; Nowak B; Ptak M; Askenase PW; Bryniarski K
    Immunology; 2015 Sep; 146(1):23-32. PubMed ID: 25808106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental Escherichia coli 06 infection in mice. II. Protective factors of immunity after immunosuppression.
    Ahlstedt S
    Scand J Infect Dis Suppl; 1980; Suppl 24():216-9. PubMed ID: 7010558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane properties and functional activity of lymphocytes from cyclophosphamide-pretreated rats.
    Guttmann RD
    J Immunol; 1974 Apr; 112(4):1594-601. PubMed ID: 4273628
    [No Abstract]   [Full Text] [Related]  

  • 40. Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy.
    Feehally J; Beattie TJ; Brenchley PE; Coupes BM; Houston IB; Mallick NP; Postlethwaite RJ
    N Engl J Med; 1984 Feb; 310(7):415-20. PubMed ID: 6229699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.